Prevention of the metabolic syndrome in IGT subjects in a lifestyle intervention: Results from the SLIM study

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 11, 2013, Pages 1147-1153

  Den Boer, A Th ^a   Herraets, I J T ^a   Stegen, J ^a   Roumen, C ^a   Corpeleijn, E ^b   Schaper, N C ^a   Feskens, E ^c   Blaak, E E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Lifestyle intervention; Metabolic syndrome; Prevention; Risk factors; Type 2 diabetes

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; THIAZIDE DIURETIC AGENT;

ADULT; AEROBIC CAPACITY; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTERVENTION STUDY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE;

LIFESTYLE INTERVENTION; METABOLIC SYNDROME; PREVENTION; RISK FACTORS; TYPE 2 DIABETES;

COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HEALTH PROMOTION; HUMANS; INCIDENCE; INDIVIDUALIZED MEDICINE; LIFE STYLE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; NETHERLANDS; NUTRITION POLICY; PATIENT EDUCATION AS TOPIC; PREVALENCE; RESISTANCE TRAINING; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84887616514     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.12.005     Document Type: Article

References (27)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J Am Med Assoc 2001, 285(19):2486-2497.
2. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002 Dec 4, 288(21):2709-2716.
3. Lorenzo C., Williams K., Hunt K.J., Haffner S.M. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care 2006 Mar, 29(3):625-630.
4. Alexander C.M., Landsman P.B., Teutsch S.M., Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52(5):1210-1214.
5. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Bonadonna R.C., et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 2003, 26(4):1251-1257.
6. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6):393-403.
7. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344(18):1343-1350.
8. Orchard T.J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005, 142(8):611-619.
9. Ilanne-Parikka P., Eriksson J.G., Lindstrom J., Peltonen M., Aunola S., Hamalainen H., et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish diabetes prevention study. Diabetes Care 2008 Jan 9, 31:805-807.
10. Phelan S., Wadden T.A., Berkowitz R.I., Sarwer D.B., Womble L.G., Cato R.K., et al. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond) 2007 Sep, 31(9):1442-1448.
11. Case C.C., Jones P.H., Nelson K., O'Brian Smith E., Ballantyne C.M. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002 Nov, 4(6):407-414.
12. Muzio F., Mondazzi L., Sommariva D., Branchi A. Long-term effects of low-calorie diet on the metabolic syndrome in obese nondiabetic patients. Diabetes Care 2005 Jun, 28(6):1485-1486.
13. Roumen C., Blaak E.E., Corpeleijn E. Lifestyle intervention for prevention of diabetes: determinants of success for future implementation. Nutr Rev 2009, 67(3):132-146.
14. Roumen C., Feskens E.J., Corpeleijn E., Mensink M., Saris W.H., Blaak E.E. Predictors of lifestyle intervention outcome and dropout: the SLIM study. Eur J Clin Nutr 2011, 65(10):1141-1147.
15. Mensink M., Corpeleijn E., Feskens E.J., Kruijshoop M., Saris W.H., de Bruin T.W., et al. Study on Lifestyle-intervention and Impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Res Clin Pract 2003, 61(1):49-58.
16. Mensink M., Feskens E.J., Saris W.H., De Bruin T.W., Blaak E.E. Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. Int J Obes Relat Metab Disord 2003, 27(3):377-384.
17. Mensink M., Blaak E.E., Corpeleijn E., Saris W.H., de Bruin T.W., Feskens E.J. Lifestyle intervention according to general recommendations improves glucose tolerance. Obes Res 2003, 11(12):1588-1596.
18. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
19. Roumen C., Corpeleijn E., Feskens E.J., Mensink M., Saris W.H., Blaak E.E. Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet Med 2008, 25(5):597-605.
20. Bot M., Spijkerman A.M., Twisk J.W., Verschuren W.M. Weight change over five-year periods and number of components of the metabolic syndrome in a Dutch cohort. Eur J Epidemiol 2010, 25(2):125-133.
21. Ferland A, Eckel RH. Does sustained weight loss reverse the metabolic syndrome? Curr Hypertens Rep 13(6):456-64.
22. Screening for type 2 diabetes. Diabetes Care 2004, 27(Suppl. 1):S11-S14.
23. Lindstrom J., Peltonen M., Eriksson J.G., Ilanne-Parikka P., Aunola S., Keinanen-Kiukaanniemi S., et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 2012, 24.
24. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368(9541):1096-1105.
25. Eriksson J., Lindstrom J., Valle T., Aunola S., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999, 42(7):793-801.
26. Swinburn B.A., Metcalf P.A., Ley S.J. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 2001, 24(4):619-624.
27. Nilsen V, Bakke PS, Gallefoss F. Effects of lifestyle intervention in persons at risk for type 2 diabetes mellitus - results from a randomised, controlled trial. BMC 11:893.